On March 8 2018 the Canadian Agency for Drugs and Technologies in Health announced that from April 2 2018, the Common Drug Review programme would accept drug submissions up to six months before a drug manufacturer's anticipated receipt of a notice of compliance (NOC) or NOC with conditions from Health Canada. This is earlier than the previous three-month deadline.(1)
For further information on this topic please contact Andrew Mandlsohn at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email ([email protected]). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
Endnotes
(1) Additional details regarding this operational change can be found in CDR Update – Issue 134.
This article was first published by the International Law Office, a premium online legal update service for major companies and law firms worldwide. Register for a free subscription.
